ArticleHeart and vessels2019
Usefulness of fibrinogen-to-albumin ratio to predict no-reflow and short-term prognosis in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
Article in Heart and vessels, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
36 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- The predictive value of laboratory parameters for no-reflow phenomenon in patients with ST-elevation myocardial infarction following primary percutaneous coronary intervention: A meta-analysis.Clinical cardiology · 2024Pooled it
- Fibrinogen-albumin ratio predicting major adverse cardiovascular outcomes post-percutaneous coronary intervention: A systematic review and exploratory meta-analysis.Clinical cardiology · 2023Pooled it
- Endothelial stress ratio as a predictor of the no-reflow phenomenon in patients with acute coronary syndrome: a retrospective study.Postepy w kardiologii interwencyjnej = Advances in interventional cardiology · 2026Article
- Fibrinogen-to-albumin ratio and risk of thrombotic diseases incidence.Thrombosis journal · 2026Article
- Association between fibrinogen-albumin ratio and outcomes in myocardial infarction: A systematic review and meta-analysis.Pakistan journal of medical sciences · 2026Article
- Thrombectomy in acute myocardial infarction: Current evidence, challenges, and emerging technologies.World journal of clinical cases · 2025Review
- Fibrinogen-to-Albumin Ratio as Predictor of Mortality in Acute Aortic Syndromes.Journal of clinical medicine · 2025Article
- Association of fibrinogen-to-albumin ratio in patients with isolated coronary artery ectasia.Journal of research in medical sciences : the official journal of Isfahan University of Medical Sciences · 2025Article
- Meta-analysis of the correlation between inflammatory response indices and no-reflow after PCI in patients with acute STEMI.American journal of translational research · 2024Review
- Postoperative fibrinogen-to-albumin ratio acting as an indicator of futile recanalization in patients with successful thrombectomy.Brain and behavior · 2023Article
- Assessment of the relationship between plasma fibrinogen-to-albumin ratio and slow coronary flow phenomenon in patients without obstructive coronary artery disease.BMC cardiovascular disorders · 2023Article
- Predictive impact of fibrinogen-to-albumin ratio (FAR) for left ventricular dysfunction in acute coronary syndrome: a cross-sectional study.European journal of medical research · 2023Article
- Prognostic Value of Fibrinogen-to-Albumin Ratio in Coronary Three-Vessel Disease.Journal of inflammation research · 2023Article
- Predilation Ballooning in High Thrombus Laden STEMIs: An Independent Predictor of Slow Flow/No-Reflow in Patients Undergoing Emergent Percutaneous Coronary Revascularization.Journal of interventional cardiology · 2023Article
- From Classic to Modern Prognostic Biomarkers in Patients with Acute Myocardial Infarction.International journal of molecular sciences · 2022Review
- Machine learning to predict no reflow and in-hospital mortality in patients with ST-segment elevation myocardial infarction that underwent primary percutaneous coronary intervention.BMC medical informatics and decision making · 2022Article
- MELD-XI score predict no-reflow phenomenon and short-term mortality in patient with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.BMC cardiovascular disorders · 2022Article
- Optical coherence tomography: evaluating the effects of stent boost subtract imaging on stent underexpansion in STEMI patients.BMC cardiovascular disorders · 2022Observational
- Article
- A nomogram risk prediction model for no-reflow after primary percutaneous coronary intervention based on rapidly accessible patient data among patients with ST-segment elevation myocardial infarction and its relationship with prognosis.Frontiers in cardiovascular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
No-reflow is one of the major complications of primary percutaneous coronary artery intervention (pPCI) in the treatment of acute ST-segment elevation myocardial infarction (STEMI). Fibrinogen-to-albumin ratio (FAR) has currently emerged as a novel inflammatory marker to predict inflammation in chronic diseases. This study aimed to investigate whether admission FAR values predicts angiographic no-reflow and short-term prognosis in all STEMI patients. A total of 510 consecutive STEMI patients who underwent successful pPCI between September 2016 and May 2018 were included in this study. Patients were divided into groups based on thrombolysis in myocardial infarction (TIMI) flow grades after pPCI. No-reflow was defined as a post-PCI TIMI flow grade of 0, 1, or 2. Angiographic success was defined as TIMI flow grade 3. Fibrinogen, hs-CRP, and admission FAR values were significantly higher among patients with no-reflow. On multivariate analysis, admission FAR was an independent predictor of angiographic no-reflow (p < 0.001). Receiver-operating characteristics analysis revealed the cut-off value of admission FAR was a predictor of no-reflow with a sensitivity of 79.59% and a specificity of 69.42%. In multivariable Cox regression models adjusted for potential confounders, admission FAR values, and LVEF, hs-CRP was independently and positively associated with the 30-day all-cause mortality. Admission FAR was associated independently and significantly with angiographic no-reflow and short-term mortality in patients with STEMI undergoing pPCI.
Indexed as
Identifiers
30993442What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.